{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:41:07Z","timestamp":1784691667701,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Key Research and Development Project of China","award":["2020YFA0112304"],"award-info":[{"award-number":["2020YFA0112304"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103451"],"award-info":[{"award-number":["82103451"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373167"],"award-info":[{"award-number":["82373167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341003"],"award-info":[{"award-number":["82341003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159301"],"award-info":[{"award-number":["92159301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Shanghai","award":["22ZR1479200"],"award-info":[{"award-number":["22ZR1479200"]}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-MSDZD2022-0489"],"award-info":[{"award-number":["Y-MSDZD2022-0489"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Key Laboratory of Breast Cancer","award":["12DZ2260100"],"award-info":[{"award-number":["12DZ2260100"]}]},{"name":"SHDC Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals","award":["SHDC12021103"],"award-info":[{"award-number":["SHDC12021103"]}]},{"name":"Shanghai Medical Innovation Research Project","award":["22Y11912700"],"award-info":[{"award-number":["22Y11912700"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Breast cancer is a highly heterogeneous disease with varied subtypes, prognoses and therapeutic responsiveness. Human leukocyte antigen class I (HLA-I) shapes the immunity and thereby influences the outcome of breast cancer. However, the implications of HLA-I variations in breast cancer remain poorly understood. In this study, we established a multiomics cohort of 1156 Chinese breast cancer patients for HLA-I investigation. We calculated four important HLA-I indicators in each individual, including HLA-I expression level, somatic HLA-I loss of heterozygosity (LOH), HLA-I evolutionary divergence (HED) and peptide-binding promiscuity (Pr). Then, we evaluated their distribution and prognostic significance in breast cancer subtypes. We found that the four breast cancer subtypes had distinct features of HLA-I indicators. Increased expression of HLA-I and LOH were enriched in triple-negative breast cancer (TNBC), while Pr was relatively higher in hot tumors within TNBCs. In particular, a higher Pr indicated a better prognosis in TNBCs by regulating the infiltration of immune cells and the expression of immune molecules. Using the matched genomic and transcriptomic data, we found that mismatch repair deficiency-related mutational signature and pathways were enriched in low-Pr TNBCs, suggesting that targeting mismatch repair deficiency for synthetic lethality might be promising therapy for these patients. In conclusion, we presented an overview of HLA-I indicators in breast cancer and provided hints for precision treatment for low-Pr TNBCs.<\/jats:p>","DOI":"10.1093\/bib\/bbae151","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T03:59:25Z","timestamp":1712807965000},"source":"Crossref","is-referenced-by-count":6,"title":["The HLA-I landscape confers prognosis and antitumor immunity in breast cancer"],"prefix":"10.1093","volume":"25","author":[{"given":"Xiao-Hong","family":"Ding","sequence":"first","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Department of Oncology , Shanghai Medical College, , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Shanghai Medical College, , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Department of Oncology , Shanghai Medical College, , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Shanghai Medical College, , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfang","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Fu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Department of Oncology , Shanghai Medical College, , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Shanghai Medical College, , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Department of Oncology , Shanghai Medical College, , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Shanghai Medical College, , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Department of Breast Surgery, Fudan University Shanghai Cancer Center; , Shanghai, 200032 , P.R. China"},{"name":"Department of Oncology , Shanghai Medical College, , Shanghai, 200032 , P.R. China"},{"name":"Fudan University , Shanghai Medical College, , Shanghai, 200032 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"issue":"1","key":"2024041103585674700_ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2024041103585674700_ref2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"16","key":"2024041103585674700_ref3","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-18-3524","article-title":"Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024041103585674700_ref4","doi-asserted-by":"crossref","first-page":"15081","DOI":"10.1038\/ncomms15081","article-title":"Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer","volume":"8","author":"Chung","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2024041103585674700_ref5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The great immune escape: understanding the divergent immune response in breast cancer subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discov"},{"issue":"9","key":"2024041103585674700_ref6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2024041103585674700_ref7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","article-title":"Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy","volume":"25","author":"Chowell","year":"2019","journal-title":"Nat Med"},{"issue":"6375","key":"2024041103585674700_ref8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"issue":"1","key":"2024041103585674700_ref9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13073-021-00997-6","article-title":"Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer","volume":"13","author":"Lu","year":"2021","journal-title":"Genome Med"},{"issue":"10","key":"2024041103585674700_ref10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jitc-2021-003371","article-title":"Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2024041103585674700_ref11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"2024041103585674700_ref12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.immuni.2021.12.006","article-title":"Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types","volume":"55","author":"Chhibber","year":"2022","journal-title":"Immunity"},{"key":"2024041103585674700_ref13","journal-title":"Nat Cancer"},{"issue":"10","key":"2024041103585674700_ref14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat Genet"},{"issue":"3","key":"2024041103585674700_ref15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"2024041103585674700_ref16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"39","key":"2024041103585674700_ref17","doi-asserted-by":"crossref","first-page":"16910","DOI":"10.1073\/pnas.1009843107","article-title":"Allele-specific copy number analysis of tumors","volume":"107","author":"Van Loo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2024041103585674700_ref18","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/molbev\/msy116","article-title":"Divergent allele advantage at human MHC genes: signatures of past and ongoing selection","volume":"35","author":"Pierini","year":"2018","journal-title":"Mol Biol Evol"},{"issue":"9","key":"2024041103585674700_ref19","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s43018-021-00226-4","article-title":"Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity","volume":"2","author":"Manczinger","year":"2021","journal-title":"Nat Cancer"},{"issue":"4","key":"2024041103585674700_ref20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1109\/TCYB.2020.3008248","article-title":"Kullback-Leibler divergence metric learning","volume":"52","author":"Ji","year":"2022","journal-title":"IEEE Trans Cybern"},{"issue":"D1","key":"2024041103585674700_ref21","doi-asserted-by":"crossref","first-page":"D423","DOI":"10.1093\/nar\/gku1161","article-title":"The IPD and IMGT\/HLA database: allele variant databases","volume":"43","author":"Robinson","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"2024041103585674700_ref22","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1158\/0008-5472.CAN-18-0689","article-title":"TIP: a web server for resolving tumor immunophenotype profiling","volume":"78","author":"Xu","year":"2018","journal-title":"Cancer Res"},{"issue":"7753","key":"2024041103585674700_ref23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","article-title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","volume":"568","author":"Chan","year":"2019","journal-title":"Nature"},{"issue":"7828","key":"2024041103585674700_ref24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41586-020-2769-8","article-title":"Repeat expansions confer WRN dependence in microsatellite-unstable cancers","volume":"586","author":"Wietmarschen","year":"2020","journal-title":"Nature"},{"issue":"17","key":"2024041103585674700_ref25","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2024041103585674700_ref26","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024041103585674700_ref27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.74.082803.133243","article-title":"DNA mismatch repair","volume":"74","author":"Kunkel","year":"2005","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"2024041103585674700_ref28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.bi.65.070196.000533","article-title":"Mismatch repair in replication fidelity, genetic recombination, and cancer biology","volume":"65","author":"Modrich","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"2024041103585674700_ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","article-title":"DNA mismatch repair in cancer","volume":"189","author":"Baretti","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"6411","key":"2024041103585674700_ref30","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"1","key":"2024041103585674700_ref31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"2024041103585674700_ref32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","article-title":"MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway","volume":"39","author":"Guan","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"2024041103585674700_ref33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","article-title":"Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities","volume":"177","author":"Vasaikar","year":"2019","journal-title":"Cell"},{"issue":"10","key":"2024041103585674700_ref34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/3\/bbae151\/57202211\/bbae151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/3\/bbae151\/57202211\/bbae151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T03:59:50Z","timestamp":1712807990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbae151\/7643339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbae151","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,27]]},"article-number":"bbae151"}}